(Bloomberg) -- Roche Holding AG’s first-quarter sales rose 5 percent, fueled by demand for a trio of breast cancer medicines.
Sales climbed to 12.4 billion Swiss francs ($12.9 billion), the Basel, Switzerland-based company said in a statement on Tuesday. That compared with the 12.3 billion-franc average of eight analyst estimates compiled by Bloomberg. Roche didn’t report first-quarter earnings.
Europe’s largest drugmaker is counting on Esbriet, a lung medicine that went on sale a year ago, and an experimental drug for multiple sclerosis for which it won expedited U.S. regulatory approval last quarter, to drive revenue growth in years ahead as products such as Lucentis age.
To contact the reporter on this story: Johannes Koch in Berlin at email@example.com. To contact the editors responsible for this story: Chitra Somayaji at firstname.lastname@example.org, Marthe Fourcade
©2016 Bloomberg L.P.